Paliwal Nidhi, Vashist Minakshi, Chauhan Minakshi
1Department of Genetics, MD University, Rohtak, India.
2Department of Obstetrics and Gynecology, Pt.B.D.S. University of Health Sciences, Rohtak, India.
3 Biotech. 2020 Mar;10(3):142. doi: 10.1007/s13205-020-2124-7. Epub 2020 Feb 27.
Among the 11 most common cancers, ovarian cancer is the fifth leading cause of death after lung, breast, colorectal and pancreatic cancer. Although diagnosis of ovarian cancer in early stages is followed by various successful treatments, no accurate and reliable method is available at present. Currently microRNAs are being explored as signature biomarkers for early detection of various types of cancer. However little information is available on expression and correlation of microRNA in ovarian cancer. In this study, we have chosen two microRNA on the basis of their altered frequency in epithelial ovarian cancer cases. The main objective of this study is to evaluate the expression of microRNA-22 and microRNA-21 along with various clinicopathological parameters. Expression level of microRNA-22 and microRNA-21 in different stages and subtypes of epithelial ovarian carcinoma has been analyzed to find out its role as a potential diagnostic biomarker. Present study has been conducted in the serum of 80 epithelial ovarian cancer patients and 80 age matched healthy women. Quantitative real time PCR was used to compare the expression of miR-22 and miR-21 between the cases and control groups. Statistical analysis showed 7.85-fold increase in miR-21 expression and 2.1-fold reduction in miR-22 expression of ovarian cancer patients. Increased serum level of miR-21 in ovarian cancer patients and decreased level of miR-22 has been correlated with advanced international federation of gynecology and obstetrics (FIGO) stage and histological sub types of epithelial ovarian cancer. Serous ovarian carcinoma was the most common cancer in the present study. Calculated fold change value for miR-21 was 3.98 and - 2.86 for miR-22 in serous ovarian cancer. Fold change value in the miR-21 expression in advanced stage was 6.29 and 4.25 in early stage. Whereas lower calculated fold change was observed for miR-22 in advanced stage than in early stage (- 2.16). Present study revealed up-regulated expression of miR-21 and down regulated expression of miR-22 in the serum of epithelial ovarian cancer patients. Both of these could be validated as good diagnostic biomarkers for early detection of ovarian cancer.
在11种最常见的癌症中，卵巢癌是继肺癌、乳腺癌、结直肠癌和胰腺癌之后的第五大死因。尽管早期诊断出的卵巢癌可采用多种成功的治疗方法，但目前尚无准确可靠的诊断方法。目前，微小RNA正被探索作为各种癌症早期检测的标志性生物标志物。然而，关于微小RNA在卵巢癌中的表达及相关性的信息却很少。在本研究中，我们基于上皮性卵巢癌病例中其频率的改变选择了两种微小RNA。本研究的主要目的是评估微小RNA-22和微小RNA-21的表达以及各种临床病理参数。分析了微小RNA-22和微小RNA-21在上皮性卵巢癌不同阶段和亚型中的表达水平，以确定其作为潜在诊断生物标志物的作用。本研究在80例上皮性卵巢癌患者和80例年龄匹配的健康女性的血清中进行。采用定量实时聚合酶链反应比较病例组和对照组中miR-22和miR-21的表达。统计分析显示，卵巢癌患者中miR-21表达增加7.85倍，miR-22表达降低2.1倍。卵巢癌患者血清中miR-21水平升高和miR-22水平降低与国际妇产科联盟（FIGO）晚期分期及上皮性卵巢癌的组织学亚型相关。浆液性卵巢癌是本研究中最常见的癌症类型。浆液性卵巢癌中miR-21的计算倍数变化值为3.98，miR-22为-2.86。晚期miR-21表达的倍数变化值为6.29，早期为4.25。而晚期miR-2所观察到的计算倍数变化低于早期（-2.16）。本研究揭示了上皮性卵巢癌患者血清中miR-21表达上调和miR-22表达下调。这两者均可被验证为早期检测卵巢癌的良好诊断生物标志物。
